Routine clinical use of biomaterials requires to foster their production. This implies the reduction of their economical and ethical costs. Our aim is to act on the biocompatibility tests (ISO10993 EU norm) which are unsustainable for small-medium industries and for the society.
In this project we foster an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials. This technology will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.
The project will allow unique quantification of the immune reaction to biomaterials at the cellular level (scientific impact), largely reducing the ethical burden of the research and the costs of biomaterial discovery (economical impact), and will Refine and Reduce protocols for biocompatibility on a single revolutionary device (regulatory impact).